Urothelial Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Bladder Cancer (143)

›

TROP2 positive	Urothelial Cancer	TROP2 positive	Urothelial Cancer	ABN202 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) ABN202 Sensitive : D AACR 2023 - 2wk	ABN202 Sensitive: D – Preclinical AACR 2023 - 2 weeks ABN202 Sensitive : D AACR 2023 - 2 weeks - (New D)
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	enfortumab vedotin Sensitive: A1 - Approval enfortumab vedotin Sensitive : A1	enfortumab vedotin Sensitive: A1 - Approval enfortumab vedotin Sensitive : A1
FGFR2 mutation	Urothelial Cancer	FGFR2 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 overexpression	Urothelial Cancer	PD-L1 overexpression	Urothelial Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	toripalimab Sensitive: A1 - Approval toripalimab Sensitive : A1	toripalimab Sensitive: A1 - Approval toripalimab Sensitive : A1
FGFR mutation	Urothelial Cancer	FGFR mutation	Urothelial Cancer	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	nivolumab + IPI-549 Sensitive: B - Late Trials nivolumab + IPI-549 Sensitive : B	nivolumab + IPI-549 Sensitive: B - Late Trials nivolumab + IPI-549 Sensitive : B
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
PD-L1 overexpression	Urothelial Cancer	PD-L1 overexpression	Urothelial Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	avelumab Sensitive: B - Late Trials avelumab Sensitive : B	avelumab Sensitive: B - Late Trials avelumab Sensitive : B
HER-2 positive	Urothelial Cancer	HER-2 positive	Urothelial Cancer	disitamab vedotin Sensitive: B - Late Trials disitamab vedotin Sensitive : B	disitamab vedotin Sensitive: B - Late Trials disitamab vedotin Sensitive : B
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
TMB-H + PD-L1 expression	Urothelial Cancer	TMB-H + PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
APOBEC mutagenesis	Urothelial Cancer	APOBEC mutagenesis	Urothelial Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	BT8009 Sensitive: B - Late Trials BT8009 Sensitive : B	BT8009 Sensitive: B - Late Trials BT8009 Sensitive : B
BRCA2 mutation	Urothelial Cancer	BRCA2 mutation	Urothelial Cancer	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Urothelial Cancer	ATM mutation	Urothelial Cancer	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
MSI-H/dMMR	Urothelial Cancer	MSI-H/dMMR	Urothelial Cancer	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1
MSI-H/dMMR	Urothelial Cancer	MSI-H/dMMR	Urothelial Cancer	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
HER-2 overexpression	Urothelial Cancer	HER-2 overexpression	Urothelial Cancer	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1

Urothelial Cancer

Associations(248)

Associations
(248)